BHSE - Coeptis Therapeutics agrees to go public through deal with SPAC Bull Horn Holdings

Coeptis Therapeutics, a biopharma compan  developing cell therapy platforms for cancer, agreed to go public through a deal with SPAC Bull Horn Holdings (NASDAQ:BHSE). BHSE ticked up 0.2%. Under the terms of the transaction, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million, according to a statement. The deal is expected to close in Q3 and Bull Horn to domesticate from the British Virgin Islands to a Delaware corporation prior to the closing. Bull Horn will be rebranded and operate as Coeptis Therapeutics  and is expected to list on Nasdaq under the ticker symbol "COEP." Bridgeway Capital Partners and Meister Seelig & Fein LLP served as financial and legal advisors, respectively, to Coeptis. Jones Trading and Ellenoff Grossman & Schole LLP served as financial and legal advisors, respectively, to Bull Horn. The deal for the biopharma company comes

For further details see:

Coeptis Therapeutics agrees to go public through deal with SPAC Bull Horn Holdings